Log in

1779 LongBio Pharma (Suzhou) Co., Ltd. HKEX · China

LongBio Pharma (Suzhou) Co. (1779) news

LongBio Pharma (Suzhou) Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1779, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest LongBio Pharma (Suzhou) Co. news

We have not published a story on LongBio Pharma (Suzhou) Co. yet. When there is news, it will appear here.

Questions about LongBio Pharma (Suzhou) Co.

What is the ticker symbol of LongBio Pharma (Suzhou) Co.?

LongBio Pharma (Suzhou) Co., Ltd. trades under the ticker 1779 on HKEX.

Where is LongBio Pharma (Suzhou) Co. listed?

LongBio Pharma (Suzhou) Co., Ltd. is listed on HKEX.

Which country or territory is LongBio Pharma (Suzhou) Co. listed under?

Our directory records LongBio Pharma (Suzhou) Co., Ltd. under China.

What does LongBio Pharma (Suzhou) Co. do?

Our directory classifies LongBio Pharma (Suzhou) Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of LongBio Pharma (Suzhou) Co.?

The ISIN recorded for LongBio Pharma (Suzhou) Co., Ltd. is CNE100007NF2.

Does aibio.space cover LongBio Pharma (Suzhou) Co.?

aibio.space lists LongBio Pharma (Suzhou) Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to LongBio Pharma (Suzhou) Co.?

Companies in our directory listed in the same country and business area as LongBio Pharma (Suzhou) Co.: EVOPOINT BIOSCIENCES CO LTD, Sichuan Kelun Pharmaceutical Co., Beijing Kawin Technology Share-Holding Co., Shanghai Serum Bio-Technology Co., Beijing Luzhu Biotechnology Co., Innovita Biological Technology Co..

Investor discussion: LongBio Pharma (Suzhou) Co.

Members talk about LongBio Pharma (Suzhou) Co. (1779). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at LongBio Pharma (Suzhou) Co., newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1) ACCOUNTANT'S REPORT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) PROFIT DISTRIBUTION PLAN FOR THE YEAR ENDED DECEMBER 31, 2025; (3) PROPOSED RE-APPOINTMENT OF AUDITOR; (4) PROPOSED GRANT OF ISSUE GENERAL MANDATE; (5) PROPOSED GRANT OF REPURCHASE GENERAL MANDATE; AND NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of LongBio Pharma (Suzhou) Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT TOPLINE DATA FROM THE PHASE II CLINICAL TRIAL IN CHINA OF LP-005 FOR THE TREATMENT OF PNH

  2. HKEXnews

    NOTICE OF EXTRAORDINARY GENERAL MEETING

  3. HKEXnews

    PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND NOTICE OF EXTRAORDINARY GENERAL MEETING

  4. HKEXnews

    PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  5. HKEXnews

    POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 10, 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST OF THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT

  7. HKEXnews

    PROPOSED CHANGE OF NON-EXECUTIVE DIRECTOR AND INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

  8. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT BLA FOR LP-003 FOR THE INDICATION OF SAR HAS BEEN ACCEPTED BY THE NMPA

  10. HKEXnews

    PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME AND THE H SHARE INCENTIVE SCHEME

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT APPLICATION FOR CLINICAL TRIAL ON LP-003 FOR THE INDICATION OF PEANUT ALLERGY APPROVED BY THE FDA

  12. HKEXnews

    STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

  13. HKEXnews

    FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

  14. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT A PHASE III CLINICAL TRIAL OF LP-003 FOR THE INDICATION OF SEASONAL AR MET PRIMARY ENDPOINTS

  16. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  17. HKEXnews

    (1) ACCOUNTANT'S REPORT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) PROFIT DISTRIBUTION PLAN FOR THE YEAR ENDED DECEMBER 31, 2025; (3) PROPOSED RE-APPOINTMENT OF AUDITOR; (4) PROPOSED GRANT OF ISSUE GENERAL MANDATE; (5) PROPOSED GRANT OF REPURCHASE GENERAL MANDATE; AND NOTICE OF ANNUAL GENERAL MEETING

  18. HKEXnews

    Announcement of Allotment Results

  19. HKEXnews

    Terms of Reference of the Nomination Committee of the Board

  20. HKEXnews

    Terms of Reference of the Remuneration Committee of the Board

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1779 on TradingView.

Listing details

LongBio Pharma (Suzhou) Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1779, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
LongBio Pharma (Suzhou) Co., Ltd.
Ticker
1779
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100007NF2
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.